A new study reports that B7-1 is not expressed on the podocytes of patients or mice with diabetic nephropathy. In contrast to the findings of some previous studies, these data suggest that targeting B7-1 on podocytes using abatacept might not be an appropriate therapeutic strategy for diabetic renal disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Packham, D. K. et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J. Am. Soc. Nephrol. 23, 123–130 (2012).
De Zeeuw, D. et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Engl. J. Med. 369, 2492–2503 (2013).
Gagliardini, E. et al. B7–1 is not induced in podocytes of human and experimental diabetic nephropathy. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2015030266.
Fiorina, P. et al. Role of podocyte B7–1 in diabetic nephropathy. J. Am. Soc. Nephrol. 25, 1415–1429 (2014).
Yu, C. C. et al. Abatacept in B7–1 positive proteinuric kidney disease. N. Engl. J. Med. 369, 2416–2423 (2013).
Reiser, J. et al. Induction of B7–1 in podocytes is associated with nephrotic syndrome. J. Clin. Invest. 113, 1390–1397 (2004).
Benigni, A. et al. Negative staining of FSGS biopsies for B7–1. N. Engl. J. Med. 370, 1261–1263 (2014).
Alachar, N., Carter-Monroe, N. & Reiser, J. Abatacept in B7-1-positive proteinuric kidney disease. N. Engl. J. Med. 370, 1263–1264 (2014).
ACCESS Trial Group. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol. 67, 487 (2015).
Garin, E. H. et al. Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int. 78, 296–302 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
G.B.A. has received research grants from Bristol–Myers Squibb, Genentech and Regulus. He lectures for Genentech and Takeda and he is a consultant for Alexion, Amgen, Boerhinger Ingelheim, Bristol–Myers Squibb, EMD Serono, Genentech, Genzyme–Sanofi, Mallinkrodt, Merck, Novartis, Pfizer, Regulus, Roche, Takeda, Teva and Up-to-Date. He has no major stock holdings or ownerships.
Rights and permissions
About this article
Cite this article
Appel, G. New data do not support use of abatacept in diabetic nephropathy. Nat Rev Nephrol 11, 692–694 (2015). https://doi.org/10.1038/nrneph.2015.178
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2015.178
This article is cited by
-
How immunosuppressive drugs may directly target podocytes in glomerular diseases
Pediatric Nephrology (2022)
-
The role of B7-1 in proteinuria of glomerular origin
Nature Reviews Nephrology (2018)
